Design Module

Design Module

The Design Module contains detailed information about the study design, including study type, allocation methods, intervention models, masking information, primary purpose, enrollment details, and biospecimen information. This module provides essential details about how the clinical trial is structured and conducted.

Design Module path is as follows:

Study -> Protocol Section -> Design Module

Design Module


Ignite Creation Date: 2025-12-24 @ 5:49 PM
Ignite Modification Date: 2025-12-24 @ 5:49 PM
NCT ID: NCT02318368
Study Type: INTERVENTIONAL
Allocation: RANDOMIZED
Primary Purpose: TREATMENT
Study: NCT02318368
Study Brief: A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Protocol Section: NCT02318368
Bio Specs (If Any):
Design Masking Infos (If Any):

Design Masking Infos

Design Masking Brief View
None View
Design Observational Models (If Any):
Design Time Perspectives (If Any):
Design Who Masked (If Any):
Enrollment Infos (If Any):

Enrollment Infos

Enrollment Type Enrollment Count View
ACTUAL 10 View
Expanded Access Types (If Any):
Phases (If Any):

Phases

Phase Brief Phase Text View
None PHASE2 View